Drug Trial Radar · NCT02033707
Effects of Hallucinogens and Other Drugs on Mood and Performance
Last checked: Nov 20, 2026Latest source record: May 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Apr 2014
Primary completion
Feb 2019
Study completion Feb 2019
Sponsor
- Lead sponsor
- Johns Hopkins UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 13, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Basic science
- Who can join
- All sexes, from 21 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This non-treatment study will investigate the effects on mood and performance caused by hallucinogens and other psychoactive compounds.
Conditions
- Healthy
Interventions
Hallucinogens and psychoactive substancesDrug
One of the following or placebo will be given: Hallucinogens: DMT, 4-phosphoryloloxy-N-diethyltryptamine, dipropyltryptamine (DPT), ketamine, dextromethorphan, mescaline, PCP, psilocybin, salvinorin-A, LSD, d-lysergic acid amide (LSA), MDMA, cannabis Sedatives/anxiolytics: alprazolam, diazepam, lorazepam, secobarbital, temazepam, triazolam, zolpidem Antihistamines: diphenhydramine, chlorpheniramine Stimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion Opioids: heroin, morphine, oxycodone, hydrocodone, methadone, codeine Other: alcohol, scopolamine, nicotine Each volunteer will receive a hallucinogen on at least one of five sessions. More drugs are listed than will be administered to increase the degree to which volunteers are "blind" to the drugs being studied. It is important that the volunteer and research staff be blinded to specific drug conditions to minimize confounding the results with expectations about the nature of drug effects.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rating of "Drug Liking" on the End of Day QuestionnaireTime frame: Completed at the end of the experimental session (approximately 8 hours after capsule administration)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.